Correlation between perioperative parecoxib use and postoperative acute kidney injury in patients undergoing radical mastectomy: a retrospective cohort analysis

Nan Xu1, Ke Pang2, Sihua Qi1* and Hongmei Wang3*

Abstract

Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely prescribed drugs worldwide. However, the effect of NSAIDS on postoperative renal function is still unclear. Few studies have assessed the effects of parecoxib on renal function. Our aim is to investigate a correlation between parecoxib and the presence or absence of AKI postoperatively after a breast cancer surgery operation.

Methods: This was a retrospective cohort study that we performed on our hospitalized database. From January 2012 to August 2021, 3542 female patients undergoing radical mastectomy were enrolled, all data including the patients’ information and laboratory results were obtained from electronic medical system. The main outcome was the incidence of AKI postoperatively. AKI was defined in accordance with the KDIGO criteria. Study groups were treated with or without parecoxib. Univariable and multivariable logistic regression analyses were performed.

Results: In our study, about 5.76% experienced AKI. The incidence rate of postoperative AKI (3.49%) within 7 days in the parecoxib group was lower than that in the control group (6.00%, \( P = 0.05 \)). Compared to the control group, the AKI's incidence was reduced by 49% (OR = 0.46; 95%CI 0.27–0.97) in parecoxib group in multivariable logistic regression analysis. There was a reduction in the incidence of postoperative AKI in other three subgroups: preoperative eGFR < 90 mL/min·1.73/m2 (OR = 0.52; 95%CI 0.27–0.97), blood loss < 1000 ml (OR = 0.48; 95%CI 0.24–0.96) and non-diabetes (OR = 0.51; 95%CI 0.26–0.98).

Conclusions: Parecoxib was associated with incidence of postoperative acute kidney injury.

Keywords: Acute kidney injury, Parecoxib, Mastectomy
Besides, among those patients with good physical conditions (low ASA grade) who underwent non-cardiac surgery, the incidence of postoperative AKI could also reach to 6% [7, 8].

There were many risk factors related to hospital AKI. The most common cause of hospital-acquired AKI is whole-body hypoperfusion, which is also independently associated with perioperative AKI [9]. Up to 60% of cases with sepsis are complicated with AKI, and approximately half of AKI cases are related to sepsis [10]. Besides, AKI was an acute worsening of renal function often associated with the use of contrast agents [11]. Meanwhile, AKI is reported to be a heterogeneous clinical syndrome, with nephrotoxic drugs accounting for 15% of AKI cases [12]. After all, the multifactorial nature of AKI and the numerous nephrotoxic drugs potentially delivered to patients make it very challenging to delineate attributable risk of AKI to specific drugs [13]. However, appropriate drugs that suppress inflammation and oxidative stress might be favorable in treating sepsis-associated AKI [14].

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used medicines in the world. Parecoxib was a kind of selective NSAIDs. Tang discovered that the AKI after the non-cardiac surgery was potential associated with parecoxib [15]. Besides, previous studies believed that COX-2 can protect the kidney from ischemia–reperfusion injury in the rats [16]. Therefore, selective COX-2 inhibitors may aggravate renal injury [17]. Above all, the effect of NSAIDS on postoperative renal function is still unclear. The objective of the study was as follows: To evaluate the correlation between postoperative AKI and the parecoxib in the patients undergoing the first surgery for primary breast cancer.

Methods
This was a retrospective cohort study in single hospital between January 1st 2012 and August 31st 2021. The inclusion criteria were as following: (1) patients > 17 years old (2) underwent primary surgical treatment of breast cancer. And the exclusion criteria were as following: (1) surgery duration less than 1 h, (2) preoperative or postoperative creatinine were missing, or (3) preoperative combined chronic kidney disease (CKD), defined as estimate glomerular filtration rate (eGFR) < 60 mL/min/1.73/m², ≥ 3 months). Fig. 1 showed the details.

Data collection
The following data was collected: (1) demographic information, including age, sex and body mass index (BMI); (2) individual history including preoperative complications and medication history; (3) laboratory data including serum creatinine and eGFR calculated using the CKD Epidemiology Collaboration formula; (4) intraoperative data including emergency, surgical grade, operative time, anesthesia method, ASA grade, amount of fluid infusion and out, intraoperative erythrocyte transfusion volume, amount of blood loss, intraoperative hypotension and vasoactive drugs and (5) postoperative outcomes such as the occurrence of AKI, admission to intensive care unit (ICU) and mortality. The missing values will be imputed by multiple imputation.

Primary outcome and definitions
Study groups were treated with or without parecoxib. Parecoxib group was only administered (40 mg or 80 mg) for one time during the induction period at the discretion of the trained anesthesiology. Whether to use the parecoxib or not was based on the doctor’s preference. Parecoxib doses larger than 80 mg were not included because the routine dose is not more than 80 mg/day based on the drug instructions. Intraoperative hypotension was defined as mean arterial pressure < 65 mmHg for a duration of at least 5 min.

Postoperative AKI was defined by Kidney Disease Improving Global Outcomes classification (KDIGO) without urine output criteria [18]. Increase in serum creatinine by > 1.5-fold from preoperative baseline within 7 days or increase in serum creatinine ≥ 0.3 mg dL⁻¹
within 48 h. The major outcome event was whether the postoperative AKI occurs or not.

**Statistical analysis**
Sample size was determined setting alpha = 0.05 and power = 0.80. Based on an estimated AKI incidence of 6.3% in control group and 3.6% in parecoxib group, we would need to include approximately 2004 patients. Empowerstats (http://www.empowerstats.com), R statistical software package and SAS statistical software were used for data analysis. Continuous variables are expressed by mean (SD), and classification variables were expressed in frequency and percentage and were analyzed using the Chi-squared test or Fisher exact test. Continuous variables between subgroups were compared by using Kruskal–Wallis test. Logistic stepwise regression was used in multivariate analysis. Bilateral test was used in all statistical analysis. The results of categorical variables were expressed as OR or ‘beta’ and 95% CI; significance was accepted at a P value of less than 0.05.

**Results**

**Parecoxib**
Overall, the parecoxib was used by 9.71% (344/3542) of the patients before the end of the surgery. The percentage of AKI in the parecoxib group (12/344, 3.49%) was lower than that control group (192/3198, 6.00%). No statistical differences between the two groups with respect to age, eGFR, alcoholism, anemia, diabetes mellitus, preoperative ACEI, ARB, diuretics, ASA grade, intraoperative erythrocyte transfusion, and intraoperative hypotension were observed (Tables 1 and 2).

**Acute kidney injury**
In total, 3542 patients were included in this study. AKI incidence was 5.76% (204/3542), with 3.92% (8/204) admission into ICU and mortality rate of 1.96% (4/204). No significant differences in age, BMI, alcohol consumption, the use of ACEI, ARB, intraoperative hemorrhage and admission into ICU were observed between groups. Baseline demographics between groups are shown in Table 3.

**Univariable analysis**
Univariable analysis was shown in the Fig. 2. By the univariable analysis, the use of parecoxib (OR 0.49; 95% CI 0.27–0.88, P = 0.017), anemia (OR 1.65; 95% CI 1.20–2.26, P = 0.002), hypertension (OR 1.78; 95% CI 1.32–2.42, P < 0.001), diabetes (OR 1.74; 95% CI 1.03–2.92, P = 0.038), the use of CCB (OR 1.55; 95% CI 1.07–2.25, P = 0.020), diuretics (OR 3.03; 95% CI 1.26–7.33, P = 0.013), eGFR (OR 0.97; 95% CI 0.96 to 0.97, P < 0.001), ASA grade III–V (OR 1.78; 95% CI 1.30–2.43, P < 0.001), intraoperative erythrocyte transfusion 100-600 ml (OR 1.66; 95% CI 1.11–2.50, P = 0.014), intraoperative erythrocyte transfusion > 1000 ml (OR 2.00; 95% CI 1.25–3.21, P = 0.004), intraoperative hemorrhage between 100-600 ml (OR 1.70; 95% CI 1.02–2.83, P = 0.043) and in fluid amount (OR 1.00; 95% CI 1.00–1.00, P < 0.001) were associated with the postoperative AKI independently. Age, BMI, alcohol consumption, the use of ACEI, ARBs, and operative duration were not correlated with AKI.

**Multivariable regression analysis**
Table 4 showed the results of Multivariable regression analysis. Parecoxib was independently associated with postoperative AKI. Besides, parecoxib might have moderate protective effects on postoperative renal function in the subgroups of eGFR < 90, blood loss < 1000 ml, and non-diabetes groups. For all the three subgroups, the administration of parecoxib leaded to a decreasingly incidence of postoperative AKI.

**Discussion**
There are so many factors related to the post-operative AKI (Fig. 2). ASA grade were related to the post-operative AKI which was similar to the previous researches [7]. The Fig. 1 suggested that intraoperative hypotension (MAP < 60 mmHg) was a risk factor to AKI, too [19]. Besides, according to the previous studies [20, 21], preoperative eGFR was one of the most important factors to AKI. The analysis suggested that preoperative eGFR was an independent risk factor in our study.

Over the past years, many researches about the NSAIDs and renal function have been reported. A previous meta-analysis suggested that the AKI was associated to NSAIDs exposure, especially in the elderly patients [22]. And another meta-analysis demonstrated selective COX-2 inhibitors was related with the increasing risk of AKI [23]. However, a study revealed that there were no statistical differences in kidney function between the groups with and without NSAIDs among elderly patients [24]. Even more, a prospective and multicenter study by STARSurg showed that NSAIDs in the postoperative was safer for the patients undergoing gastrointestinal surgery. And the low dose of flurbiprofen axetil (50-100 mg) decrease the rate of AKI after breast cancer surgery which was in the scope mentioned in previous studies (1.0–31.0%) [27–29]. The incidence of AKI in cancer patients was high, which was closely related to their cachexia or renal injury drugs [30]. And another study showed that non-selective NSAIDs (acetaminophen) was not related
to the AKI among the patients undergoing surgery for renal carcinoma [31]. However, administration of parecoxib nearly reached statistical significance in our study (Table 2). One possible explanation might be that breast tumor growth have elevated the level of inflammation [32] and reduced the potential renoprotective effect of parecoxib. Furthermore, parecoxib showed its potential renoprotective effect in the multivariate analysis (OR = 0.46, 95%CI = 0.24–0.86) in Table 4. Furthermore, the results revealed that parecoxib may still has a stable effect on the partial patients receiving breast cancer surgery as following: eGFR < 90 mL/min\·1.73/m², blood loss < 1000 ml and non-diabetes, which represented preoperative glomerular perfusion

### Table 1 Baseline demographic data of study population group by parecoxib

| Clinical features                  | Control Group (n = 3198) | Parecoxib Group (n = 344) | P  |
|-----------------------------------|--------------------------|---------------------------|----|
| Age (year)                        | 45.30 ± 9.53             | 45.15 ± 9.81              | 0.921 |
| BMI                               | 22.68 ± 6.35             | 21.96 ± 2.73              | 0.049 |
| eGFR                              | 98.85 ± 21.02            | 100.14 ± 21.55            | 0.270 |
| Alcohol consumption               | 39 (1.22%)               | 3 (0.87%)                 | 0.572 |
| Anemia                            | 648 (20.26%)             | 59 (17.15%)               | 0.170 |
| Hypertension                      | 714 (22.33%)             | 57 (16.57%)               | 0.014 |
| Diabetes mellitus                 | 169 (5.28%)              | 14 (4.07%)                | 0.333 |
| ACEI                              | 57 (1.78%)               | 5 (1.45%)                 | 0.659 |
| ARB                               | 34 (1.06%)               | 2 (0.58%)                 | 0.397 |
| CCB                               | 426 (13.32%)             | 28 (8.14%)                | 0.006 |
| Diuretics                         | 35 (1.09%)               | 4 (1.16%)                 | 0.908 |
| ASA grade                         |                          |                           | 0.932 |
| I–II                              | 2572 (80.43%)            | 276 (80.23%)              |    |
| III–V                             | 626 (19.57%)             | 68 (19.77%)               |    |
| Operative time (min)              |                          |                           | <0.001 |
| ≤ 60                              | 442 (13.82%)             | 27 (7.85%)                |    |
| 61–120                            | 841 (26.30%)             | 75 (21.80%)               |    |
| 121–180                           | 812 (25.39%)             | 98 (28.49%)               |    |
| > 180                             | 1103 (34.49%)            | 144 (41.86%)              |    |
| Intraoperative erythrocyte Transfusion, mL (%) | 2465 (77.08%)          | 315 (77.91%)              | 0.396 |
| < 100                             | 355 (11.10%)             | 29 (8.43%)                |    |
| 100–600                           | 173 (5.41%)              | 22 (6.40%)                |    |
| > 1000                            | 205 (6.41%)              | 25 (7.27%)                |    |
| Intraoperative hemorrhage, mL (%) |                          |                           | 0.004 |
| < 100                             | 1030 (32.21%)            | 81 (23.55%)               |    |
| 100–600                           | 1728 (54.03%)            | 205 (59.59%)              |    |
| > 1000                            | 236 (7.38%)              | 26 (7.56%)                |    |
| Intraoperative hypotension         |                          |                           | 0.216 |
| 345 (10.79%)                      | 47 (13.66%)              | 47 (13.66%)               |    |
| In fluid amount (10 mL/24 h)      | 937.50 (625.00–1369.79)  | 1083.33 (666.67–1500.00)  | <0.001 |
| Out fluid amount (10 mL/24 h)     | 333.33 (145.83–541.67)   | 291.67 (125.00–479.17)    | 0.004 |

AKI Acute Kidney Injury, BMI Body Mass Index, eGFR estimated Glomerular Filtration Rate, ACEI Angiotensin-converting Enzyme Inhibitors, ARB Angiotensin Receptor Blockers, CCB Calcium-channel Blockers, ASA American Society of Anesthesiologists. Data are expressed as number of patients (%) or Mean ± SD

### Table 2 Incident of postoperative AKI in different dose parecoxib

|                  | Parcoxib(0 mg) | Parecoxib(40 mg or 80 mg) | P   |
|------------------|----------------|---------------------------|-----|
| AKI              | 192 (6.00%)    | 12 (3.49%)                | 0.051 |
| AKI Stages       | 0.225          |                           |     |
| 0                | 3006 (94.00%)  | 332 (96.51%)              |     |
| 1                | 140 (4.38%)    | 8 (2.33%)                 |     |
| 2                | 25 (0.78%)     | 1 (0.29%)                 |     |
| 3                | 27 (0.84%)     | 3 (0.87%)                 |     |

AKI Acute Kidney Injury. Data are expressed as number of patients (%)
and filtration disorder, relatively good cardiovascular status and perfusion. Overall, parecoxib (40 or 80 mg) has a potential protective effect on postoperative AKI.

The mechanism by which parecoxib protects the patient against postoperative AKI is not clear. But it maybe correlated with decreasing the postoperative kidney inflammatory reaction [33]. High-dose flurbiprofen axetil may destroy the inflammatory balance in the tubules [25]. Besides the clinical studies above, an animal experiment by Takaku indicated that a single dose of parecoxib could reduce the inflammation and tubular renal injury in the rats model of ischemic tubular necrotizing nephritis caused by acute hemorrhagic shock [34].

A limitation of the present study was its retrospective nature, and further research involving multi-center, prospective studies is required. And, we only chose the patients above 18 years who received the first breast cancer surgery, and the scope of application of the conclusion was relatively narrow.

### Table 3  Baseline demographic data of study population group by AKI

| Clinical features                  | Without AKI(n = 3338) | With AKI(n = 204) | P     |
|-----------------------------------|-----------------------|-------------------|-------|
| Age (years)                       | 45.29 ± 9.56          | 45.06 ± 9.59      | 0.63  |
| BMI                               | 22.64 ± 6.22          | 22.18 ± 3.46      | 0.15  |
| eGFR                              | 100.28 ± 18.88        | 77.61 ± 37.41     | <0.001|
| Alcohol consumption               | 40 (1.20%)            | 2 (0.98%)         | 0.78  |
| Anemia                            | 649 (19.44%)          | 58 (28.43%)       | 0.002 |
| Hypertension                      | 705 (21.12%)          | 66 (32.35%)       | <0.001|
| Diabetes mellitus                 | 166 (4.97%)           | 17 (8.33%)        | 0.03  |
| ACEI                              | 58 (1.74%)            | 4 (1.96%)         | 0.81  |
| ARB                               | 33 (0.99%)            | 3 (1.47%)         | 0.50  |
| CCB                               | 417 (12.44%)          | 37 (18.14%)       | 0.02  |
| Diuretics                         | 33 (0.99%)            | 6 (2.94%)         | 0.01  |
| ASA grade                         |                       |                   | <0.001|
| I–II                              | 2704 (81.01%)         | 144 (70.59%)      |       |
| III–V                             | 634 (18.99%)          | 60 (29.41%)       |       |
| Operative time (min)              |                       |                   | 0.004 |
| ≤ 60                              | 446 (13.36%)          | 23 (11.27%)       |       |
| 61–120                            | 882 (26.42%)          | 34 (16.67%)       |       |
| 121–180                           | 852 (25.52%)          | 58 (28.43%)       |       |
| > 180                             | 1158 (34.69%)         | 89 (43.63%)       |       |
| Intraoperative erythrocyte Transfusion, mL (%) | 0.004          |                   |       |
| < 100                             | 2596 (77.77%)         | 137 (67.16%)      |       |
| 100–600                           | 353 (10.58%)          | 31 (15.20%)       |       |
| 601–1000                          | 181 (5.42%)           | 14 (6.86%)        |       |
| > 1000                            | 208 (6.23%)           | 22 (10.78%)       |       |
| Intraoperative Hemorrhage, mL (%)  |                       |                   | 0.12  |
| < 100                             | 1054 (31.58%)         | 57 (27.94%)       |       |
| 100–600                           | 1824 (54.64%)         | 109 (53.43%)      |       |
| 601–1000                          | 240 (7.19%)           | 22 (10.78%)       |       |
| > 1000                            | 220 (6.59%)           | 16 (7.84%)        |       |
| In fluid amount (10 mL/24 h)      | 937.50 (625.00–1375.00) | 1135.42 (729.17–1526.04) | <0.001|
| Out fluids amount (10 mL/24 h)    | 312.50 (145.83–541.67) | 333.33 (187.50–625.00) | 0.02  |
| Intraoperative hypotension         | 363 (10.87%)          | 29 (14.21%)       | 0.005 |
| Parecoxib                         | 332 (9.95%)           | 12 (5.88%)        | 0.05  |
| Admission to ICU                  | 90 (2.70%)            | 8 (3.92%)         | 0.30  |
| Death                             | 7 (0.21%)             | 4 (1.96%)         | <0.001|

**AKI** Acute Kidney Injury, **BMI** Body Mass Index, **eGFR** estimated Glomerular Filtration Rate, **ACEI** Angiotensin-converting Enzyme Inhibitors, **ARB** Angiotensin Receptor Blockers, **CCB** Calcium-channel Blockers, **ASA** American Society of Anesthesiologists, Intraoperative hypotension: MAP < 60 mmHg, **ICU** Intensive Care Unit. Data are expressed as number of patients (%) or Mean ± SD.
Conclusions

Parecoxib (40 or 80 mg) may correlate with relatively low risk of postoperative AKI, in adult patients undergoing breast cancer surgery. Further prospective, multiple centers research are needed to confirm the protective effects on postoperative AKI.

Acknowledgements

This work was supported by grant from Wujieping Medical Foundation (320.6750.2020-08-25).

Table 4 Multivariable regression analysis of postoperative AKI associated with parecoxib

| AKI Variable | Control | Parecoxib(40 or 80 mg) |
|--------------|---------|------------------------|
|              |         | Model 1 | Model 2 | Model 3 |
| All cases    | 1       | 0.49 (0.27, 0.88) 0.017 | 0.48 (0.26, 0.87) 0.016 | 0.46 (0.24, 0.80) 0.015 |
| EGFR < 90    | 1       | 0.58 (0.32, 1.04) 0.069 | 0.56 (0.31, 1.02) 0.058 | 0.52 (0.27, 0.97) 0.041 |
| Blood loss < 1000 ml | 1 | 0.52 (0.27, 1.00) 0.051 | 0.51 (0.27, 0.98) 0.045 | 0.48 (0.24, 0.96) 0.037 |
| Non-diabetes | 1       | 0.56 (0.30, 1.04) 0.066 | 0.54 (0.29, 1.01) 0.053 | 0.51 (0.26, 0.98) 0.045 |
| AKI Stages   | 1       | -0.04 (-0.07, -0.00) 0.030 | -0.04 (-0.07, -0.00) 0.028 | -0.04 (-0.07, -0.01) 0.013 |

Model 1: Non-adjusted
Model 2: Adjusted for age, BMI, alcohol consumption, anemia, hypertension, diabetes mellitus, ACEI, CCB, diuretics, ASA, anesthesia method, in fluids, out fluids, transfusion, and hemorrhage
Model 3: Adjusted for model 2 plus ARB, preoperative eGFR, anesthesia method, operative time and intraoperative hypotension

Authors’ contributions

NX reviewed and analyzed the data and wrote the manuscript. SHQ guided the research and revised the manuscript. NX contributed to the conception and design of the study. MHW aided the research, KP conceived and designed the study, and revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

Funding

This work was supported by grant from Wujieping Medical Foundation (320.6750.2020-08-25).
Availability of data and materials
The analyzed data sets generated during the study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study was approved by the IRB of The Fourth Affiliated Hospital of Harbin Medical University (2021-SCILLSC-12). Because of retrospective study, informed consent was waived.

Consent for publication
Not applicable.

Competing interests
The authors declare they have no competing interests.

Author details
1 The Department of Anesthesiology, The Fourth Affiliated Hospital of Harbin Medical University, 37 Yiyuan Street, Nangang District, Harbin, Heilongjiang, China. 2 The Department of Anesthesiology, The Third Xiangya Hospital of Central South University, 138 Tongzepo Road, Yuehu District, Changsha, Hunan, China. 3 The Department of Pain, The Fourth Affiliated Hospital of Harbin Medical University, 37 Yiyuan Street, Nangang District, Harbin, Heilongjiang, China.

Received: 25 November 2021 Accepted: 4 May 2022

Published online: 20 May 2022

References

1. Kim BR, Yoon S, Song GY, Lee S, Bahk JH, Nam K. The impact of total intravenous anesthesia versus inhalation anesthesia on acute kidney injury after major abdominal surgery: a propensity score analysis. J Anesth. 2021;35(1):112–21.
2. Silverton NA, Hall JE, Melendez NP, Harris B, Harley JS, Parry SR, et al. Intraoperative urinary biomarkers and acute kidney injury after cardiac surgery. J Cardiothorac Vasc Anesth. 2021;35(6):1691–700.
3. Faubel S, Chawla LS, Chertow GM, Goldstein SL, Jaber BL, Liu KD. Ongoing clinical trials in AKI. Clin J Am Soc Nephrol. 2012;7(5):861–73.
4. Tang Y, Li H, Guo Z. Prediction of ICU admission after orthopedic surgery in elderly patients. Pak J Med Sci. 2021;37(4):1179–84.
5. Mossanen JC, Pracht J, Jansen TU, Buendigens L, Stoppe C, Goetzenich A, Struck J, Autschbach R, Marx G, Tacke F. Elevated soluble urokinase plasminogen activator receptor and proenkephalin serum levels predict the development of acute kidney injury after cardiac surgery. Int J Mol Sci. 2017;18(8):1662.
6. O’Connor ME, Hewson RW, Kirwan CJ, Ackland GL, Pearse RM, Prove JR. Acute kidney injury and mortality 1 year after major non-cardiac surgery. Br J Surg. 2017;104(7):868–76.
7. Iyigun M, Akyut G, Tosun M, Milerick M, Aksu U, Güler T, Toraman F. Perioperative risk factors of acute kidney injury after non-cardiac surgery: a multicenter, prospective, observational study in patients with low grade American Society of Anesthesiologists physical status. Am J Surg. 2019;218(3):457–61.
8. Doleman B, Blackwell J, Karangiz A, Butt W, Bhatta A, Lund JN, Williams JP. Anaesthetists stress is induced by patient ASA grade and may impair non-technical skills during intubation. Acta Anaesthesiologica Scand. 2016;60(7):910–6.
9. Ikeda M, Swide T, Vayl A, Lahm T, Anderson S, Huchtens MP. Estrogen administered after cardiac arrest and cardiopulmonary resuscitation ameliorates acute kidney injury in a sex- and age-specific manner. Crit Care. 2015;19:332.
10. Li Y, Zhai P, Zheng Y, Zhang J, Liu YY, Peng Z. Csf2 Attenuated sep- signaling pathway is involved in the ameliorative effects of ginseng polysaccharides against cisplatin-induced nephrotoxicity in mice. ACS Omega. 2021;6(13):8988–96.
11. Ehrmann S, Helms J, Joret A, Martin-Lefevre L, Quenot JP, Herbrecht JE, Benzekri-Lefevre D, Robert R, Deschay A, Belliec F, et al. Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury. Ann Intensive Care. 2019;9(1):106.
12. Islam MS, Miao L, Yu H, Han Z, Sun H. Ethanol extract of illicium henryi attenuates LPS-induced acute kidney injury in mice via regulating inflammation and oxidative stress. Nutrients. 2019;11(6):1412.
13. Tang YZ, Zeng P, Liao Y, Qin Z, Zhang H, Li B, Ouyang W, Li D. Correlation between perioperative parecoxib use and postoperative acute kidney injury in patients undergoing non-cardiac surgery: a retrospective cohort analysis. BMJ Open. 2021;11(8):e047840.
14. Calistro Neto JP, Torres RoC, Gonçalves GM, Silva Lmd, Domingues MAC, Módolo NSp, Barros GAmD. Parecoxib reduces renal injury in an ischemia/reperfusion model in rats. Acta Cir Bras. 2015;30(4):270–6.
15. Patel NSA, Cuzzocrea S, Collino M, Chatterjee PK, Mazzon E, Britti D, Yaoqbo MM, Thiemermann C. The role of cyclooxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo. Eur J Pharmacol. 2007;562(1–2):148–54.
16. Foti KE, Wang D, Chang AR, Selvin E, Sarnak MJ, Chang TI, Munttner P, Creaser J. Potential implications of the 2021 KDIGO blood pressure guide- line for adults with chronic kidney disease in the United States. Kidney Int. 2021;99(3):686–9.
17. Gregory A, Stapelfeldt WH, Khanha AK, Smischny NJ, Boero UJ, Chen Q, Stevens M, Shaw AD. Intraoperative Hypotension Is Associated With Adverse Clinical Outcomes After Noncardiac Surgery. Anesth Analg 2020. Online ahead.
18. Sawhney S, Mitchell M, Marks A, Fluck N, Black C. Long-term prognosis after acute kidney injury (AKI): what is the role of baseline kidney function and recovery? A systematic review. BMJ Open. 2015;5(1):e006497.
19. Toda Y, Sugimoto K. AKI after pediatric cardiac surgery for congenital heart diseases-recent developments in diagnostic criteria and early diagnosis by biomarkers. J Intensive Care. 2017;5:49.
20. Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2017;18(1):256.
21. Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: a systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015;26(4):285–91.
22. Amatradua JG, Katz R, Peralta CA, Estrella MM, Sarathy H, Fried LF, Newman AB, Panic RH, Xu J, Samkaj MJ, et al. Association of non-steroidal anti-inflammatory drugs with kidney health in ambulatory older adults. J Am Geriatr Soc. 2021;69(3):726–34.
23. Wang D, Xiao W, Li B, Zhao Y, Liu Z, Zhang Y, et al. Perioperative use of flurbiprofen axetil on renal function after transurethral prostatectomy: a prospective randomized controlled study. J Nanomater. 2021;2021(1):1–7.
24. Wang D, Yang SK, Zhao MX, Tang YZ, Ou-Yang W, Zhang H, Xiao J. Low dose of flurbiprofen axetil decrease the rate of acute kidney injury after operation: a retrospective clinical data analysis of 9915 cases. BMC Nephrol. 2020;21(1):52.
25. Kim M, Brady JE, Li G. Variations in the risk of acute kidney injury across intraabdominal surgery procedures. Anesth Analg. 2014;119(5):1121–32.
26. Bteker M, Dayan A, Tekkşen AJ, Can MM, Tayci I, Ilhan E, Sahin G. Incidence, risk factors, and outcomes of perioperative acute kidney injury in noncardiac and nonvascular surgery. Am J Surg. 2014;207(1):53–9.
27. Vaara ST, Bellomo R. Postoperative renal dysfunction after noncardiac surgery. Curr Opin Crit Care. 2017;23(5):440–6.
28. Lepuroumo T, Lepuroumo U, Alinoula I, Frägilä A, Andronesi A, Micu E, Banu M, Costea R, Ismail G. Renal replacement therapy in cancer patients with acute kidney injury (Review). Exp Ther Med. 2021;22(3):864.
29. Varela-Santoyo E, Escamilla-López M, Izquierdo-Tolosa CD, Arroyave-Ramírez AM, Buera-Varequez GH, Donantes-Heredia R, Motola-Kuba D, Ruiz-Morales JM. Impact of the type of analgesic therapy on postoperative complications of patients with kidney cancer undergoing nephrectomy. Oncology. 2020;98(2):117–22.
32. Javaid N, Choi S. Toll-like receptors from the perspective of cancer treatment. Cancers (Basel). 2020;12(2):297.
33. Sato Y, Yanagita M. Immune cells and inflammation in AKI to CKD progression. Am J Physiol Renal Physiol. 2018;315(6):F1501–12.
34. Takaku M, da Silva AC, Iritsu NI, Vianna PTG, Castiglia YMM. Effects of a single dose of parecoxib on inflammatory response and ischemic tubular injury caused by hemorrhagic shock in rats. Pain Res Treat. 2018;2018:8375746.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.